Effects of atrial natriuretic peptides and furosemide in conscious dogs.
Effects of ANF(8-33) and Auriculin A on renal variables were investigated in conscious water-diuretic dogs. The two substances were injected intravenously (1.08 micrograms/kg in 3 min) or ANF(8-33) was infused (0.2 microgram/kg X min in 20 min). The effects were compared to those of an equinatriuretic dose of furosemide (1.0 microgram/kg X min). Injections caused increases in sodium excretion, diuresis, and osmolar clearance. No significant change in exogenous creatine clearance (CCREA) occurred. Infusion of ANF(8-33) decreased blood pressure by 14% (P less than 0.01) and increased sodium excretion by a factor of 10 (P less than 0.01). The natriuresis was a function of increases in diuresis and urinary sodium concentration, the latter by a factor of 6 (P less than 0.01). Diuresis and free-water clearance (CH2O) increased by 60% (P less than 0.01), but urine osmolality did not change significantly. After the infusion a significant decrease in PAH clearance (CPAH) (P less than 0.01) was observed. Filtration fraction (FF) did not change. The furosemide natriuresis appeared later than that of ANF without significant deviations in diuresis, CH2O, CCREA, CPAH, and FF; urine osmolality increased by 35% (P less than 0.01). The effects of ANF(8-33) differ from those of furosemide in several ways. First, the onset of natriuresis is faster, second, the natriuresis is associated by marked increases in diuresis and free-water clearance but not in urine osmolality; and third, natriuresis is followed by a reduction in renal blood flow. The rapid natriuresis of ANF can occur without changes in glomerular filtration rate.
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage / Q000494:pharmacology*; D003243:Consciousness; D003404:Creatinine / Q000378:metabolism; D004231:Diuresis / Q000187:drug effects*; D004285:Dogs; D005260:Female; D005665:Furosemide / Q000008:administration & dosage / Q000494:pharmacology*; D007038:Hypotonic Solutions / Q000008:administration & dosage; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D009318:Natriuresis / Q000187:drug effects*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D010130:p-Aminohippuric Acid / Q000378:metabolism
D007038:Hypotonic Solutions; D010446:Peptide Fragments; D005665:Furosemide; D009320:Atrial Natriuretic Factor; C044120:atrial natriuretic factor prohormone (8-33); D003404:Creatinine; D010130:p-Aminohippuric Acid